HKSTP Welcomes Rohto Advanced Research Hong Kong Limited to Science Park’s Biotechnology Ecosystem

Kunio Yamada, Chairman and CEO, Rohto Pharmaceutical Co., Ltd. (left) and Albert Wong, CEO of Hong Kong Science and Technology Parks Corporation (right) officiated at the opening of Rohto Advanced Research Hong Kong Limited who joins Hong Kong Science Park to promote the R&D on regenerative medicine, cell culture technologies in Hong Kong.

Hong Kong, 6 September 2019 – Hong Kong Science and Technology Parks Corporation (HKSTP) announced the latest Science Park addition to its biomedical technology ecosystem – Rohto Advanced Research Hong Kong Limited (RARHK), a subsidiary of Rohto Pharmaceutical Co., Ltd in Japan.

Rohto Pharmaceutical Co., Ltd is the Japanese manufacturer and marketer of pharmaceutical products, cosmetics and functional foods. Since the launch of gastrointestinal medicine Ikatsu in 1899, the company has continuously developed high value-added non-prescription medicine and health and beauty products and supplements.

Currently, Rohto Pharmaceutical Co., Ltd is is conducting a Phase I/II study of allogenic adipose-derived mesenchymal stromal cells against liver cirrhosis in Japan, and has developed an automated cell culture and storage system which allows large scale manufacturing at low cost.

Leveraging on the infrastructure and ecosystem at Hong Kong Science Park, RARHK will conduct basic research on mesenchymal stromal cells and other possible areas for the upcoming new era of cell therapies.